Guillermo J. Ruiz-Argüelles David Gómez-Almaguer Andres Gomez congrats, México it’s so proud of you The EBMT #EBMT25

I was thawing a CAR-T cell unit, almost done only to realize the patient had not yet been lymphodepleted 😱😱😱 Suddenly, I woke up, drenched in sweat and realized it was all nightmare. And that is the only time I have been happy not to have access to CAR-T cells.

"My son the Doctor " this Street name in Punta del Este Uruguay. I have a son who is a Doctor. Nice feeling.

Honored and a great privilege to represent patients and colleagues from our continent LABMT SBTMO ASH #ASH24 #BMTsm #CARTcells

My son Andrés in Highlights of ASH. Today in Uruguay. RIC conditioning in ALL with MRD negative is a valid option. @BMT. @LABMT

Jorge Cortes as always..,, nice presentation CML in Highlights of ASH.

Hematology World. Martha, Belinda, Antonio and my self Punta del Este . ASH & LATAM working in the LATP program. April 2025

Decentralized Point-of-Care Manufacturing of CD19 Chimeric Antigen Receptor T Cells in Mexico. Co-authored by Andres Gomez Read more. brnw.ch/21wSkpC

CAR-T should also be a therapeutic opportunity in LMICs. POC manufacturing promotes CAR-T democratization.

Los pacientes mexicanos necesitan CAR-T. Aunque debimos recibir respuesta hace 3 meses, llevamos 6 meses esperando aprobación de COFEPRIS para iniciar ensayos clínicos en pacientes. Nosotros listos para iniciar!

Orgullosos de compartir nuestra más reciente publicación en Expert Review of Hematology: nuevas combinaciones de fármacos para mieloma múltiple recién diagnosticado. ¿Cómo podemos mejorar los tratamientos actuales en México?

🧵 1/9 📢 Just published! "Advances in the Treatment of AML: Implications for Low- and Middle-Income Countries" 🔓 Open access: mdpi.com/2227-9059/13/5… 🧬 This thread breaks down key insights—and how they can help improve AML care in resource-limited settings.

This is much needed research! Congrats Héctor A. Vaquera Dr. Luis Villela Perla Colunga

A new tool for ITP? Impresive results, just a single case but very provocative. Just 4 doses of Teclistamab.

Nine years ago, we showed this pioneering study from Monterrey explored low-dose imatinib + nilotinib in CP-CML patients after imatinib failure. Dual therapy showed promising results. Nowadays TKIs combinations are an exciting hot topic.

🇬🇹 🇬🇹 Guatemala is going to change. We’re doing things right. It fills me with pride to use my knowledge and passion for hematology to lead this project. Forever proud of where I trained — Monterrey,Mx ❤️ #Hematology #Transplant #Guatemala

Sesión académica extraordinaria: "Mieloma múltiple en recaída" 🧬🧫 Coord. Dr. David Gómez-Almaguer 👨‍⚕️ Expertos: Dra. Aline G. Ramírez Alvarado 🇲🇽 Dr. Raj Chakraborty 🇺🇸 🗓️ Miércoles 25 de junio | 19:00 hrs (GMT-6) 🔗 ¡Regístrate!: amehac.org/sesiones ¡No te lo pierdas!

SQ blinatumomab is highly effective in R-R ALL with CR/CRh rate of 77%, MRD-negativity rate of 91%, and 12-month OS rate of 63-70%. The 250 µg/500 µg dose was selected as the recommended phase 2 dose. MD Anderson Cancer Center #Leukemia doi.org/10.1016/s2352-… #leusm

She relapsed after quadruplet and AHSCT for plasma cell leukemia. Teclistamab was administered and MRD negative was obtained. Now she is recovering from allo HSCT. No CAR-T cells available. She is a fighter!